ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded down 15.6% on Wednesday . The company traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.98 ($0.06). 68,204,375 shares were traded during mid-day trading, an increase of 164% from the average session volume of 25,820,418 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Stock Performance
The business’s 50-day moving average is GBX 2.06 and its two-hundred day moving average is GBX 1.83. The stock has a market capitalization of £21.65 million, a PE ratio of -520.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Nebius Group: Market Overreaction or Real AI Disruption?
- 3 Fintech Stocks With Good 2021 Prospects
- The Best Way to Invest in Gold Is…
- Differences Between Momentum Investing and Long Term Investing
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
